Nutriband Inc. (NASDAQ: NTRB), a company focused on transdermal pharmaceutical products, has confirmed that its outstanding warrants will expire as scheduled on September 30, 2026, at 5 p.m. EDT. The company stated there will be no extension or repricing of the warrants, which carry a current strike price of $6.43 per share. Warrant holders have until the expiration date to exercise their warrants at that price. After expiration, any unexercised warrants will expire in their entirety and be removed from the NTRBW Nasdaq listing.
As of the announcement, Nutriband has 910,904 warrants outstanding. If all warrants are exercised at the $6.43 strike price, the company could receive approximately $5.86 million in potential proceeds. This capital infusion could support Nutriband's ongoing development of its lead product, an abuse-deterrent fentanyl patch that incorporates the company's AVERSA(TM) abuse-deterrent technology. According to the company, AVERSA(TM) can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The decision to let the warrants expire without extension or repricing is notable because it provides a clear deadline for warrant holders and signals confidence in the company's current share price and future prospects. Warrant holders who choose to exercise will do so at $6.43 per share, which may be above or below the market price at the time of exercise. The removal of the warrants from the Nasdaq listing after expiration will simplify Nutriband's capital structure. For investors, the potential $5.86 million in proceeds could strengthen the company's balance sheet and fund research and development, but it also depends on warrant holders' willingness to exercise. If fewer warrants are exercised, the company would receive less capital.
Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products. Its abuse-deterrent fentanyl patch is the lead product under development, and the AVERSA(TM) technology represents a potential solution to the ongoing opioid crisis by reducing the risk of abuse and accidental exposure. The company's website is www.nutriband.com, though any material contained in or derived from the website is not part of the press release.
For investors seeking the latest news and updates relating to NTRB, the company maintains a newsroom at https://nnw.fm/NTRB. The full press release can be viewed at https://nnw.fm/5DRKN.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The platform aims to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public. Terms of use and disclaimers applicable to all content provided by NetworkNewsWire are available at https://www.NetworkNewsWire.com/Disclaimer.
